Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: Steve Johnston who wrote (734)	12/26/1999 9:54:00 PM
From: spyhunter	Read Replies (1) \| Respond to of 756

Anyone out there following IVAX?? Chris

To: Steve Johnston who wrote (734)	8/4/2000 6:16:47 PM
From: kendall harmon	Respond to of 756

IVX, good article here << Miami, Aug. 4 (Bloomberg) -- Ivax Corp., one of the largest makers of generic drugs, said it agreed to buy closely held respiratory-medicine marketer Wakefield Pharmaceuticals Inc. to expand its sales force as it prepares for new drug approvals. Financial terms weren't disclosed. Wakefield, based in Alpharetta, Georgia, has a sales staff of more than 50 people, Ivax said. Miami-based Ivax had sales of $656.3 million last year. The purchase will help Ivax sell its growing line of proprietary products such as the Easi-Breathe asthma inhaler, currently sold in Europe and awaiting U.S. regulatory approval, the company said. Ivax expects the inhaler and several other treatments to be approved in 2002-2003. ``This is the start of a core group that will expand over time as we get more approval for our branded products,'' said Neil Flanzraich, Ivax vice chairman and president. Shares of Miami-based Ivax fell 4, or 8 percent, to 45 3/4 on the American Stock Exchange. Analysts attributed the decline to rumors the company would encounter delays in getting U.S. Food and Drug Administration approval for its generic equivalent of Bristol- Myers Squibb Co.'s $1.5 billion-a-year cancer medicine Taxol. Those rumors were unfounded, analysts said. ``It's a slow summer afternoon, and there are rumors out there, but we've checked and there's nothing to them,' said Jeffrey Kraws, an analyst at Gruntal & Co. Flanzraich said earlier today that approval on the drug was ``imminent.'' ``We've said we expect it this summer, and we're in August now, so that pretty much means this month,'' he said. ``You can never pinpoint when the FDA will actually come through, but there are no delays or other issues at all.'' >> quote.bloomberg.com